{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:21:53Z","timestamp":1775496113958,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Regadenoson is a well-established selective A\n                    <jats:sub>2A<\/jats:sub>\n                    adenosine receptor agonist able to induce coronary vasodilation, thus serving as an effective agent for stress myocardial perfusion imaging with several imaging modalities. Regadenoson is approved to be used in adults, but it is also used off-label in the pediatric setting. This paper summarizes the findings from the published literature on the use of regadenoson in pediatric populations undergoing stress CMR. Publications were identified via literature search on PubMed and Google Scholar and assessed for efficacy, adverse events, imaging-related aspects, use of stress-reversal agents, posology, and use of anesthesia. Nine publications met the criteria for this paper, reporting on a cumulative total of 276 pediatric patients, male and female, age range 2 months \u2013 18 years, evaluated with regadenoson-based stress CMR between 2017 and 2025. Authors of all identified publications were based in the USA. In seven out of nine studies the regadenoson posology was weight-based (6\u201310\u00a0\u00b5g\/kg). Several different contrast agents were used alongside regadenoson. No serious adverse events (AEs) were reported. All minor AEs reported in the studies were either resolved via stress-reversal agent, or self-resolved by the end of the exam. Using a random effects model that considers both within-study variance and between-study variance, the average heart rate at rest was found to be 81.9 [75.1; 88.7], and at stress 119.6 [114.9; 124.2] (delta\u2009=\u200937.7\u00a0bpm). In the United States, regadenoson is being used off-label for stress perfusion CMR in pediatric populations. Published reports indicate that regadenoson is efficacious and well-tolerated in this population.\n                  <\/jats:p>","DOI":"10.1007\/s00246-026-04252-w","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:50:28Z","timestamp":1775490628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric Use of Regadenoson for Stress Cardiovascular Magnetic Resonance Imaging: A Systematic Literature Review"],"prefix":"10.1007","author":[{"given":"Dimosthenis E.","family":"Gkotsis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaron","family":"Raiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Peillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"8","key":"4252_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jcmg.2011.04.015","volume":"4","author":"OR Coelho-Filho","year":"2011","unstructured":"Coelho-Filho OR, Seabra LF, Mongeon FP et al (2011) Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient\u2019s sex. JACC Cardiovasc Imaging 4(8):850\u2013861","journal-title":"JACC Cardiovasc Imaging"},{"issue":"13","key":"4252_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/eurheartj\/ehac033","volume":"43","author":"C Bucciarelli-Ducci","year":"2022","unstructured":"Bucciarelli-Ducci C, Ajmone-Marsan N, Di Carli M, Nicol E (2022) The year in cardiovascular medicine 2021: imaging. Eur Heart J 43(13):1288\u20131295","journal-title":"Eur Heart J"},{"issue":"1","key":"4252_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","volume":"22","author":"CM Kramer","year":"2020","unstructured":"Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E (2020) Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 22(1):17","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"4252_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2214\/AJR.14.13546","volume":"204","author":"A Varga-Szemes","year":"2015","unstructured":"Varga-Szemes A, Meinel FG, De Cecco CN, Fuller SR, Bayer RR 2nd, Schoepf UJ (2015) CT myocardial perfusion imaging. AJR Am J Roentgenol 204(3):487\u2013497","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"4252_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.nuclcard.2003.12.002","volume":"11","author":"GA Beller","year":"2004","unstructured":"Beller GA, Bergmann SR (2004) Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol 11(1):71\u201386","journal-title":"J Nucl Cardiol"},{"issue":"12","key":"4252_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00259-015-3139-x","volume":"42","author":"HJ Verberne","year":"2015","unstructured":"Verberne HJ, Acampa W, Anagnostopoulos C et al (2015) EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT\/CT: 2015 revision. Eur J Nucl Med Mol Imaging 42(12):1929\u20131940","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4252_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jcmg.2009.09.024","volume":"3","author":"TR Porter","year":"2010","unstructured":"Porter TR, Xie F (2010) Myocardial perfusion imaging with contrast ultrasound. JACC Cardiovasc Imaging 3(2):176\u2013187","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"4252_CR8","first-page":"4","volume":"49","author":"A Cuocolo","year":"2005","unstructured":"Cuocolo A, Acampa W, Imbriaco M et al (2005) The many ways to myocardial perfusion imaging. Q J Nucl Med Mol Imaging 49(1):4\u201318","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"6","key":"4252_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s12350-011-9441-5","volume":"18","author":"AE Arai","year":"2011","unstructured":"Arai AE (2011) The cardiac magnetic resonance (CMR) approach to assessing myocardial viability. J Nucl Cardiol 18(6):1095\u20131102","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"4252_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/jmri.20075","volume":"19","author":"LE Thomson","year":"2004","unstructured":"Thomson LE, Kim RJ, Judd RM (2004) Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging 19(6):771\u2013788","journal-title":"J Magn Reson Imaging"},{"issue":"11","key":"4252_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1161\/01.CIR.0000120294.67948.E3","volume":"109","author":"K Shan","year":"2004","unstructured":"Shan K, Constantine G, Sivananthan M et al (2004) Role of cardiac magnetic resonance imaging in the assessment of myocardial viability. Circulation 109(11):1328\u20131334","journal-title":"Circulation"},{"issue":"2","key":"4252_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0735-1097(94)90424-3","volume":"23","author":"MD Cerqueira","year":"1994","unstructured":"Cerqueira MD, Verani MS, Schwaiger M et al (1994) Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 23(2):384\u2013389","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4252_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/RLI.0b013e3181dfa2f2","volume":"45","author":"G Bastarrika","year":"2010","unstructured":"Bastarrika G, Ramos-Duran L, Rosenblum MA et al (2010) Adenosine-stress dynamic myocardial CT perfusion imaging: initial clinical experience. Invest Radiol 45(6):306\u2013313","journal-title":"Invest Radiol"},{"issue":"13","key":"4252_CR14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","volume":"54","author":"W Al Jaroudi","year":"2009","unstructured":"Al Jaroudi W, Iskandrian AE (2009) Regadenoson: a new myocardial stress agent [published correction appears in J Am Coll Cardiol. 2009 Oct 20;54(17):1635]. J Am Coll Cardiol 54(13):1123\u20131130","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4252_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnmt.109.065581","volume":"38","author":"SG Johnson","year":"2010","unstructured":"Johnson SG, Peters S (2010) Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol 38(3):163\u2013171","journal-title":"J Nucl Med Technol"},{"issue":"1","key":"4252_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/10489040-000000000-00000","volume":"10","author":"KP Garnock-Jones","year":"2010","unstructured":"Garnock-Jones KP, Curran MP (2010) Regadenoson. Am J Cardiovasc Drugs 10(1):65\u201371","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"4252_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00000441-198710000-00005","volume":"294","author":"RR Ruffolo","year":"1987","unstructured":"Ruffolo RR Jr. (1987) The pharmacology of dobutamine. Am J Med Sci 294(4):244\u2013248","journal-title":"Am J Med Sci"},{"issue":"1","key":"4252_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.RES.36.1.185","volume":"36","author":"RR Tuttle","year":"1975","unstructured":"Tuttle RR, Mills J (1975) Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36(1):185\u2013196","journal-title":"Circ Res"},{"issue":"1","key":"4252_CR19","volume":"13","author":"KO Elkholy","year":"2021","unstructured":"Elkholy KO, Hegazy O, Okunade A et al (2021) Regadenoson stress testing: a comprehensive review with a focused update. Cureus 13(1):e12940","journal-title":"Cureus"},{"issue":"1","key":"4252_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0735-1097(00)01054-8","volume":"37","author":"H Tanaka","year":"2001","unstructured":"Tanaka H, Monahan KD, Seals DR (2001) Age-predicted maximal heart rate revisited. J Am Coll Cardiol 37(1):153\u2013156","journal-title":"J Am Coll Cardiol"},{"key":"4252_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fphys.2018.00226","volume":"9","author":"PT Nikolaidis","year":"2018","unstructured":"Nikolaidis PT, Rosemann T, Knechtle B (2018) Age-predicted maximal heart rate in recreational marathon runners: a cross-sectional study on Fox\u2019s and Tanaka\u2019s equations. Front Physiol 9:226","journal-title":"Front Physiol"},{"issue":"4","key":"4252_CR22","doi-asserted-by":"publisher","DOI":"10.1148\/ryct.2019190061","volume":"1","author":"JC Wilkinson","year":"2019","unstructured":"Wilkinson JC, Doan TT, Loar RW et al (2019) Myocardial stress perfusion MRI using regadenoson: a weight-based approach in infants and young children. Radiol Cardiothorac Imaging 1(4):e190061","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"1","key":"4252_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12968-021-00803-7","volume":"23","author":"N Husain","year":"2021","unstructured":"Husain N, Watanabe K, Berhane H et al (2021) Multi-parametric cardiovascular magnetic resonance with regadenoson stress perfusion is safe following pediatric heart transplantation and identifies history of rejection and cardiac allograft vasculopathy. J Cardiovasc Magn Reson 23(1):135","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"4252_CR24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s00246-021-02675-1","volume":"42","author":"JA Hutchens","year":"2021","unstructured":"Hutchens JA, Johnson TR, Payne RM (2021) Myocardial perfusion reserve in children with Friedreich ataxia. Pediatr Cardiol 42(8):1834\u20131840","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"4252_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14740\/cr1323","volume":"12","author":"B Schloss","year":"2021","unstructured":"Schloss B, Bekiroglu I, O\u2019Connor C et al (2021) Hemodynamic and respiratory effects of regadenoson during radiologic imaging in infants and children. Cardiol Res 12(6):329\u2013334","journal-title":"Cardiol Res"},{"issue":"1","key":"4252_CR26","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.jocmr.2025.101880","volume":"27","author":"N Das","year":"2025","unstructured":"Das N, Vu E, Popescu A et al (2025) Feasibility and safety of regadenoson stress perfusion protocol in pediatric transplant patients under general anesthesia. J Cardiovasc Magn Reson 27(1):101880","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"4252_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00247-016-3762-0","volume":"47","author":"CV Noel","year":"2017","unstructured":"Noel CV, Krishnamurthy R, Moffett B et al (2017) Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson. Pediatr Radiol 47(3):280\u2013289","journal-title":"Pediatr Radiol"},{"issue":"5","key":"4252_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1017\/S1047951118000094","volume":"28","author":"LE Hernandez","year":"2018","unstructured":"Hernandez LE (2018) Myocardial stress perfusion magnetic resonance in children with hypertrophic cardiomyopathy. Cardiol Young 28(5):702\u2013708","journal-title":"Cardiol Young"},{"issue":"9","key":"4252_CR29","volume":"9","author":"SG Patel","year":"2022","unstructured":"Patel SG, Husain N, Rigsby CK et al (2022) Safety and efficacy of regadenoson for pediatric stress perfusion cardiac MRI with quantification of myocardial blood flow. Children (Basel) 9(9):1332","journal-title":"Children (Basel)"},{"issue":"7","key":"4252_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.amjcard.2019.06.033","volume":"124","author":"TT Doan","year":"2019","unstructured":"Doan TT, Wilkinson JC, Loar RW et al (2019) Regadenoson stress perfusion cardiac magnetic resonance imaging in children with Kawasaki disease and coronary artery disease. Am J Cardiol 124(7):1125\u20131132","journal-title":"Am J Cardiol"},{"issue":"11","key":"4252_CR31","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00247-023-05738-y","volume":"53","author":"M Ganigara","year":"2023","unstructured":"Ganigara M, Sharma B, Doctor P et al (2023) Tolerability and efficacy of a reduced dose adenosine stress cardiac magnetic resonance protocol under general anesthesia in infants and children. Pediatr Radiol 53(11):2188\u20132196","journal-title":"Pediatr Radiol"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-026-04252-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:50:29Z","timestamp":1775490629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-026-04252-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":31,"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s00246-026-04252-w","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are currently full-time employees of GE HealthCare, a manufacturer and distributor of Rapiscan (active ingredient: regadenoson) in Europe. No other competing interests such as: financial interests, funding, or non-financial interests are present, other than employment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}